Improving the analysis of rare cancer cells using advanced microfluidics
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics
This study is looking at new ways to find important changes in cancer cells that can help doctors understand how tumors grow and resist treatment, so that patients with solid tumors can receive more personalized and effective therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-10775716 on NIH RePORTER |
What this research studies
This research focuses on enhancing the detection of epigenetic changes in cancer cells, which are crucial for understanding tumor behavior and treatment resistance. By utilizing innovative technologies that preserve molecular interactions, the study aims to improve the sensitivity of assays that identify specific epigenetic biomarkers in clinical samples. This could lead to better precision medicine approaches for cancer treatment, allowing for more tailored therapies based on individual epigenetic profiles. Patients with solid tumors may benefit from the findings as they could lead to more effective treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who may have epigenetic alterations influencing their cancer progression.
Not a fit: Patients with non-solid tumors or those whose cancer does not involve epigenetic modifications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with more accurate diagnoses and personalized treatment options for various cancers.
How similar studies have performed: Other research has shown promise in utilizing epigenetic biomarkers for cancer treatment, indicating that this approach could lead to significant advancements in the field.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Beebe, David J — University of Wisconsin-Madison
- Study coordinator: Beebe, David J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.